Champions Oncology, Inc.
CSBRAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | $12.00(+26%) | $9.55 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Craig-Hallum | maintain | Buy | Mar 12, 2025 |
| Craig-Hallum | maintain | Buy | Dec 12, 2024 |
| Craig-Hallum | upgrade | Hold →Buy | Sep 12, 2024 |
| Craig-Hallum | downgrade | Buy →Hold | Mar 13, 2024 |
| Roth MKM | maintain | Buy | Sep 22, 2023 |
| Roth Capital | maintain | Buy | Mar 15, 2021 |
| Benchmark | maintain | Speculative Buy →Buy | Nov 18, 2019 |
| Roth Capital | maintain | Buy | Sep 20, 2019 |
| Janney Montgomery Scott | downgrade | Buy →Neutral | Jul 24, 2019 |
| Janney Capital | downgrade | Buy →Neutral | Jul 24, 2019 |
| Craig-Hallum | maintain | Buy | Jul 17, 2018 |
| Dawson James | maintain | Buy | May 15, 2018 |
Earnings History
Next report: Dec 15, 2026 · EPS est. $0.02| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Sep 10, 2026 | $0.05 | $-0.01 | $15.2M | $15.0M |
| Jul 27, 2026 | $0.01 | $-0.05 | $13.8M | $12.9M |
| Mar 12, 2026 | $-0.02 | $0.09 | $16.6M | $16.6M |
| Dec 15, 2025 | $0.02 | $0.08 | $15.0M | $14.0M |
| Sep 15, 2025 | $-0.03 | $-0.01 | $14.0M | $13.5M |
| Jul 23, 2025 | $-0.13 | $-0.20 | $12.4M | $12.0M |
| Mar 11, 2025 | $0.31 | $-0.01 | $17.0M | $12.9M |
| Dec 11, 2024 | $0.05 | $0.01 | $13.5M | $13.1M |
News
CSBR and BDSX ride on distinct oncology growth drivers, but which stock looks more compelling amid contrasting performance and valuations? Let's dive in.
Azenta (NASDAQ: AZTA - Get Free Report) and Champions Oncology (NASDAQ: CSBR - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Profitability This table compares Azenta and Champions Oncology's
Champions Oncology's first-quarter fiscal 2027 results record revenue and margin growth, stronger adjusted earnings and surging data-license revenues.
Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call Transcript
Champions Oncology NASDAQ: CSBR reported first-quarter fiscal 2027 revenue growth, improved margins and its fifth consecutive quarter of positive adjusted EBITDA, as both its translational oncology services and data licensing businesses contributed to results.
Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 HACKENSACK, NJ / ACCESS Newswire / September 10, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its first quarter of fiscal 2027, ended July 31, 2026. First Quarter and Recent Highlights: Revenue of $15.2 million, an increase of 8.8% year over year Oncology services margin of 51%, compared with 43% in the prior-year peri…